Translational relevance
Aspirin has been shown to reduce the incidence of colorectal cancer (CRC), and accumulating evidence suggests that aspirin may improve the clinical outcome of CRC patients following surgical resection. Recent data from large observational studies indicate that the survival benefit of aspirin may be confined to specific molecular subsets defined by phosphatidylinositol 3-kinase (PI3KCA) mutation status and cyclooxygenase-2 (COX-2) expression levels. Furthermore, regular aspirin intake was found to be associated with a reduced risk of developing CRCs with wild-type BRAF alleles, but not tumors with activating V600E point mutations. Together, these data suggest that aspirin may selectively exert its antitumor effects in specific molecular subsets, thereby identifying potential predictive biomarkers for aspirin efficacy in CRC patients.
Abstract
Abundant epidemiological evidence indicates that regular and long term use of aspirin is associated with a significant reduction in the incidence of colorectal cancer (CRC). The long duration of aspirin needed to prevent CRC is believed to be due to inhibition of precursor lesions known as adenomas, whose recurrence is inhibited by aspirin in randomized trials. Aspirin intake has also been associated with a statistically significant improvement in patient survival after curative resection of CRC in large observational studies. In these cohorts, the survival benefit of aspirin was shown to depend upon the level of cyclooxygenase-2 (COX-2) expression in the primary CRC. More recent analysis of patient tumors from these observational cohorts suggests that the benefit of aspirin may be limited to specific molecular subtypes. Aspirin intake following CRC resection was associated with a significant improvement of survival in patients whose tumors carried mutant, but not wild-type, copies of the phosphatidylinositol 3-kinase (PI3KCA) gene, especially tumors that overexpressed COX-2. A mechanistic explanation is suggested by the finding that inhibition of COX-mediated prostaglandin E2 synthesis by aspirin attenuates PI3K signaling activity that is known to regulate cancer cell proliferation and survival.
Aspirin has also been shown to reduce the incidence of CRCs bearing wild-type, but not mutant alleles of the BRAF V600E oncogene. While provocative, the potential utility of these molecular markers for predicting aspirin efficacy awaits prospective evaluation in clinical trials. If validated, these finding may support a personalized approach to using aspirin for the therapy of CRC.
Acetylsalicylic acid was first synthesized in 1853 and used for its analgesic and antiinflammatory properties. Aspirin acts on cyclooxygenase (COX) enzymes that regulate the synthesis of prostaglandins (PGs) and related eicosanoids from arachidonic acid (Fig. 1) . It inhibits constitutively expressed COX-1 as well as the COX-2 isoform which is upregulated at sites of inflammation (1). Selective COX-2 inhibitors were developed to reduce gastrointestinal injury but were later found to have cardiovascular toxicities (2) . Large observational studies have demonstrated an association of regular and long-term aspirin intake with a significant reduction in the incidence (3) (4) (5) and mortality from colorectal cancer (CRC) (3, 6 (Table 1) . Importantly, the ability of aspirin to reduce CRC incidence became evident only after regular use for more than 10 years (multivariate RR=0.59; 95%CI, 0.42 to 0.82; P for trend <0.001). The relative risk was further reduced as the number of aspirin tablets (325 mg) taken per week increased (0.5-1.5 vs 2-5 vs 6-14 vs >14; P trend =0.001), indicating that the chemopreventive effect was dependent upon both the dose and duration of aspirin intake (7), suggesting the importance of cumulative dosage as a determinant of aspirin efficacy in these settings.
The explanation as to why a prolonged duration of aspirin intake, varying between studies from 4 years to greater than 10 years (5, 8) , is needed to reduce the incidence of CRC is likely due to a chemopreventive effect of aspirin on colorectal adenomas that are precursor lesions of CRC. In preclinical models, aspirin inhibits the development of colorectal adenomas and their progression to carcinoma (9) . Using colorectal adenomas as a surrogate end point for CRC, earlier randomized and controlled trials of aspirin for the chemoprevention of CRC were negative(10, 11); however, more recent randomized trials have consistently demonstrated aspirin's ability to decrease adenoma recurrence in patients with prior colorectal adenomas or cancer (12, 13) , although the minimally effective dose remains unclear (14) . The failure of earlier studies to detect a chemopreventive effect of aspirin may be due, in part, to the need for prolonged follow-up as studies reporting no reduction in CRC incidence initially (11, 15, 16) often noticed an effect after a longer interval ranging from 56 months to around 17 years (8, 17) .
A recent study involving 39,876 women aged 45 years or older who were enrolled in the Women's Health Study found that alternate day dosing of low dose aspirin (100 mg) taken for 10 or more years significantly reduced the incidence of CRC in women (HR=0.80; 95% CI, 0.67-0.97; P=0.021), especially in the proximal colon (17) . After 18 years, the incidence of CRC was 20% lower in the aspirin group than in the placebo group and was accompanied by a significant increase in self-reported gastrointestinal toxicities (HR for GI bleeding 1.14; 95% CI, 1.06-1.22; P <0.001). In a high-risk population, i.e., patients with prior colon cancer, a prospective study involving 635 participants found that treatment with 325 mg/day aspirin over a mean duration of 30.9 months was associated with a statistically significant reduction in the risk of recurrent colorectal adenomas (13) . Similar to aspirin, the selective COX-2 inhibitor, celecoxib, has been shown to effectively reduce adenoma recurrence in patients with prior adenomas in randomized trials (18, 19) . In a 20 year follow-up of 5 randomized trials, aspirin at doses of at least 75 mg daily taken for several years reduced the long-term incidence and mortality from CRC, with the benefit being greatest for cancers of the proximal colon ( aspirin treatment (600 mg/day for >2 years) was shown to significantly reduce the incidence of CRCs (N=508) (HR= 0.41; 95% CI, 0.19-0.86; P=0.02) in LS patients during prolonged followup (mean 55·7 months; range 1-128) (8) .
In a recent report of patients within the NHS and HPFS who developed CRC, a potential predictive biomarker for aspirin efficacy was found. Regular aspirin intake was associated with a significant reduction in the incidence of CRCs with wild-type (WT), but not mutant BRAF V600E ( (24, 25) . COX-2 inhibition was unable to suppress proliferation in KRAS-mutated cells which suggests that this may also be the case in BRAF V600E mutated CRC cells (26) . The finding that aspirin can selectively reduce the incidence of BRAF-WT CRCs awaits prospective validation, and studies to identify the mechanism underlying its potential predictive impact are awaited.
In addition to its role in the prevention of CRC, data also indicate a role for aspirin as an adjuvant agent in patients with resected CRC ( the NHS and HPFS studies (27) where 1279 patients with non-metastatic CRCs were identified retrospectively, and then categorized based on aspirin usage post diagnosis (≥ two 325-mg tablets per week). During a median follow-up of 11.8 years from diagnosis, aspirin use post diagnosis (N=549) was associated with a statistically significant reduction in both CRC-specific mortality(HR=0.71; 95% CI 0.53-0.95, P=0.02) and overall mortality (HR=0.79; 95% CI 0.65-0.97, P=0.03) compared to non-aspirin users. Stratifying tumors based on expression of COX-2 revealed that the survival benefit from aspirin use was confined to patients whose primary tumors overexpressed COX-2 proteins (CRC-specific multivariate HR=0.39; 95%CI 0.20-0.76).
In contrast, a subgroup analysis of study participants who reported aspirin use prior to a CRC diagnosis indicated no mortality reduction even when aspirin use was continued post-diagnosis (n=21)(P interaction = 0.09) (27) Further support for an effect of aspirin on micrometastases derives from 5 different randomized trials of aspirin for the prevention of vascular events that showed that aspirin use (80-325 mg/day) decreased the risk of metastases from CRC at diagnosis, as well as the risk of subsequent metastasis at follow-up in patients who were initially metastasis-free (HR=0.26; 95% CI 0.11-0.57; P=0.0008) (31) . As was seen for its chemopreventive effects, the presumed 
anti-metastatic effects of aspirin also appear to be dose-dependent in that an increase in postdiagnosis aspirin dosage from 0.5-5 to >6 tablets per week led to a modest improvement in survival benefit In the NHS and HPFS patient cohorts (P trend =0.04) (27) . Taken together, these studies suggest that aspirin warrants further evaluation as an adjuvant agent to eradicate micrometastases. In this regard, the ASCOLT study is the first prospective randomized placebo-controlled trial to evaluate aspirin as adjuvant therapy in resected CRC. In this study, Acting through its cell surface receptors EP1-EP4, PGE 2 regulates cellular processes important in cancer development (Fig. 1) . PGE 2 acts through EP4 to activate Tcf/Lef signaling through a PI3-kinase-dependent pathway (40) . Inhibition of PGE 2 signaling by aspirin may therefore, attenuate PI3K activity in PIK3CA mutant cancers (41) . In addition to inhibiting PGE 2 , aspirin has been shown to inhibit mTOR, a downstream effector of the PI3K pathway by activation of AMPK (Adenosine Monophosphate-activated Protein Kinase) in CRC cells (42) .
The mechanisms underlying the anti-tumor properties of aspirin include both COX-dependent and -independent effects (43). PGE 2 stimulates angiogenesis by induction of VEGF (Vascular endothelial growth factor) and bFGF (basic Fibroblast growth factor) (44) , and can modulate the WNT/β-catenin pathway to enable an epithelial-to-mesenchymal transition, a critical event for metastasis (45) . COX-independent mechanisms contribute to the anti-tumor effects of aspirin by inhibiting PPARδ (peroxisome proliferator-activated receptor) (46) and the NF-κB pathway (47) (48) (49) . Aspirin can also exert immunomodulatory effects by altering chemokines (CCL2 and CXCL10) that lead to decreased numbers of myeloid-derived suppressor cells (MDSCs) and an increase in cytotoxic CD8+ T-cells (50) . Both aspirin and selective COX-2 inhibitors can modulate apoptosis (51, 52) , including in human colorectal epithelial tissues (53) , and cancer stem cells may be more sensitive to NSAIDs-induced apoptosis relative to differentiated cells which is relevant to eradicating micrometastases (54) .
From a clinical perspective, identifying the lowest dose of aspirin that can achieve antitumor effects while minimizing potential toxicities is critical. In a prior study, we reported that the 81 mg daily aspirin dose suppressed PGE 2 levels equally as did the 650 mg daily dosage in the colorectal mucosa of patients with prior adenomas (55) . The anti-tumor benefits of aspirin are achieved with a trade-off of increased toxicities, as described in a meta-analysis of 22 randomized trials of aspirin for vascular disease prevention. Most notable are the risks of gastrointestinal toxicities, mainly ulcers and GI bleeding (RR=1.62; 95% CI, 1.25-2.09), or intracranial bleeding (RR=1.65; 95% CI, 1.06-5.99). In the meta-analysis, there was no difference in the rate of adverse events between patients receiving low dose (75-162.5 mg/day) vs standard dose(162.5-325 mg/day) aspirin (56) . The risks vs potential benefits of aspirin must always be considered when advocating its use in patients. While aspirin is currently not recommended for patients at average risk of developing CRC or in patients with removal of prior adenomatous polyps, its use in high risk patients such as those with advanced adenomas or prior CRC may be warranted on an individualized basis. However, unresolved issues include the minimally effective dose, optimal duration, and the role of aspirin in patients already undergoing colonoscopic surveillance. For the adjuvant therapy of CRC, existing data justify the prospective evaluation of aspirin in this setting and a clinical trial (ASCOLT) is ongoing.
Furthermore, the addition of celecoxib to standard chemotherapy with FOLFOX is being studied in an ongoing phase III adjuvant therapy trial (CALBG 80702). More than a century after it was first synthesized, the therapeutic benefits of aspirin continue to emerge. Aspirin has been shown to protect against the recurrence of colorectal adenomas and carcinomas, and compelling evidence suggests its efficacy as an adjuvant agent in a molecular subset. Specifically, aspirin may selectively and potently inhibit colon cancer recurrence and improve survival in patient tumors with PI3KCA mutations. While this finding is compelling, the modest number of patients whose tumors carried PIK3CA mutations and who also used aspirin in these studies necessitates caution in their interpretation and underscores the need for prospective validation. Aspirin is currently being studied as adjuvant therapy in an ongoing trial in CRC patients (ASCOLT), and another adjuvant study evaluates the benefit of adding celecoxib to FOLFOX in node-positive colon cancer patients (CALGB-80702). In both trials, a comparison of survival based on PIK3CA mutation status will be performed and will yield further efficacy data. Prospective evaluation will be challenging due to the relatively small number of patients whose tumors carry the PIK3Ca mutation, and studies will also need to address the issue of duration of aspirin therapy needed to achieve clinical benefit. Research into the mechanistic basis of aspirin's efficacy in PIK3CA mutated CRCs is eagerly awaited. In an era of targeted therapy that is increasing health care costs, aspirin is an inexpensive and well tolerated drug that may prove to be an effective agent to prevent colon cancer recurrence. 
